Longitude Capital

What Longitude Capital does

Longitude Capital is a private venture growth investment firm headquartered in Menlo Park, California with a second office in Boston, Massachusetts. Founded in 2006 by Juliet Bakker, Patrick Enright, and Marc Galletti (who began investing together at Pequot Ventures in 2002), the firm specializes in healthcare investments across three verticals: biotechnology, medical technology, and health solutions. The firm invests in both privately held and publicly traded companies using a variety of structures including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and equity-linked instruments. Since 2006, the firm has raised over $2 billion across six funds and has collaborated on more than 90 new investments and 150 follow-on investments.

The firm's portfolio spans clinical-stage and commercial-stage companies with clinically de-risked assets, targeting attractive returns within a 3-5 year horizon. Notable current and historical holdings include 89bio (acquired by Roche for up to ~$3.5B), Tourmaline Bio (acquired by Novartis), Nalu Medical (acquired by Boston Scientific for $533M), Bolt Medical (acquired by Boston Scientific), Veradermics (NYSE: MANE IPO), CG Oncology, Jazz Pharmaceuticals, and dozens of other life sciences companies across oncology, liver disease, neurology, inflammation, rare disease, and medical devices. The team of approximately 24 professionals includes six Managing Directors with deep operating backgrounds from McKinsey, Cardinal Health, GRAIL, Jazz Pharmaceuticals, Bristol Myers Squibb, and leading investment banks.

Revenue is generated through traditional fund management: management fees on committed capital across the six funds, plus carried interest on successful realizations. The firm monetizes exits through M&A (the majority of liquidity events) and IPOs (most recently Veradermics in February 2026). Limited partners access fund information through a Dynamo Software-powered portal. As an SEC-registered investment adviser, the firm maintains a regulatory compliance program led by a Chief Compliance Officer and supported by ACA Global. There are no externally disclosed management fee rates, fund vintage sizes, or LP identities in the source material.

Name

Longitude Capital

Legal name

Longitude Capital

Website

https://longitudecapital.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Longitude Capital is a private healthcare-focused venture growth firm that has raised over $2 billion across six funds since 2006 to invest in biotechnology, medical technology, and health solutions companies from offices in Menlo Park and Boston.

Ownership category

akta.pro rank

Product category

Venture Capital / Healthcare Private Equity

NAICS

Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239), Other Financial Vehicles (52599)

SIC

Investment Advice (6282)

akta.pro industry

PRIMARYFSANACAB

Healthcare & Life Sciences Growth Equity

Financial & Insurance/Private Equity & Venture Capital/Growth Equity Firms

SECONDARYFSANAAAD

Sector-Focused Venture Capital (Vertical Specialists)

Financial & Insurance/Private Equity & Venture Capital/Venture Capital Firms

SECONDARYFSANAAAC

Late-Stage Venture Capital (Series C+)

Financial & Insurance/Private Equity & Venture Capital/Venture Capital Firms

Keywords

• Venture capital investing
• Healthcare private equity
• Biotechnology investment
• Medical technology financing
• Growth stage capital

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others

Revenue model

1. Fund Management Fees & Carried Interest: As a venture capital firm, Longitude Capital generates revenue primarily through management fees and carried interest on its six healthcare-focused funds, with over $2 billion raised since 2006. The firm invests across biotechnology, medical technology, and health solutions via traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and equity-linked instruments.
2. Public Equity Returns: Returns from investments in publicly traded companies via open market purchases, PIPEs, and other equity/equity-linked instruments. The firm has a dedicated Senior Analyst focused on public equities.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Longitude Capital is a venture growth investment firm that makes equity and equity-linked investments in healthcare companies across three categories: biotechnology, medical technology, and health solutions. Since 2006, the firm has raised over $2 billion across six funds and deploys capital through traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity-linked instruments, with a target investment horizon of three to five years.

Product overview

Longitude Capital is a venture capital firm (not a traditional product company) that specializes in making venture growth investments in healthcare companies across three core categories: Biotechnology, Medical Technology, and Health Solutions. The firm has raised over $2 billion across six investment funds since 2006 and operates from offices in Menlo Park, California and Boston, Massachusetts. Its core offering consists of the Longitude Capital Venture Growth Investment Funds, which deploy capital through structures including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity and equity-linked instruments. The firm maintains an LP Portal (powered by Dynamo Software) for limited partners, and supports its portfolio companies with strategic planning, capital raising, and liquidity event execution. The three named investment focus areas (Biotechnology, Medical Technology, and Health Solutions) function as sub-categories within the core investment fund product rather than as standalone products. The firm's team has collaborated on over 90 new investments and 150 follow-on investments across the life sciences industry.

Differentiator

Problem solved

Functional benefit

Products and services

• Longitude Capital Venture Growth Investment Funds Six venture growth investment funds raised since 2006, totaling over $2 billion in committed capital. The funds invest across three categories (biotechnology, medical technology, and health solutions), targeting clinical-stage and commercial-stage companies with clinically de-risked assets via traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity-linked instruments, with a three to five year return horizon.
• LP Portal (Dynamo Software) Limited partner access portal powered by Dynamo Software, providing limited partners with fund information, reporting, and investor relations content. Accessible at dynamo.dynamosoftware.com.

Quantifiable outcome

• Raised over $2 billion across six funds since 2006
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Frazier Life Sciences: Frazier Life Sciences is a dedicated healthcare venture capital firm investing across biopharma and medtech stages. It is a direct peer, having co-led or led multiple recent Longitude-backed rounds (AirNexis, cAMPfield, Veradermics Series C) and competes for the same clinical-stage healthcare opportunities.
• RA Capital Management: RA Capital is a healthcare-focused investment manager running crossover and venture strategies. It is a direct peer, participating alongside Longitude in financings (e.g., cAMPfield Series A) and pursuing the same biotech and medtech opportunities through both private rounds and public equities.
• OrbiMed: OrbiMed is one of the largest dedicated healthcare investment firms globally, covering venture through public equities. It is a direct peer in healthcare venture growth, having co-invested with Longitude in AirNexis and overlapping on similar clinical-stage assets.
• Novo Holdings (Novo Ventures): Novo Holdings' venture arm invests globally in biopharma and biotech. It is a direct peer in healthcare venture growth, having co-invested with Longitude in cAMPfield Series A and pursuing the same therapeutic-area investment theses.
• Forbion: Forbion is a European life sciences venture capital firm investing across stages in biotech. It is a direct peer in healthcare venture growth, having participated in cAMPfield's Series A and competing for clinical-stage biotech opportunities globally.
• SR One (GSK): SR One is the venture capital arm of GSK, investing in biotech and therapeutics. It is a direct peer in healthcare venture growth, having led the Veradermics Series C and co-invested in AirNexis alongside Longitude.
• Venrock: Venrock is a long-established venture capital firm with a dedicated healthcare practice. It is a direct peer in healthcare venture growth, having participated in cAMPfield's Series A and targeting similar biopharma and medtech opportunities.
• Abingworth: Abingworth is a specialist life sciences investment firm with venture and crossover strategies. It is a direct peer, having participated in cAMPfield's Series A and pursuing comparable clinical-stage biotech opportunities.

Broad incumbents

• Baker Bros. Advisors: Baker Bros. is a large, long-tenured healthcare-focused investment adviser running concentrated public and private biotech strategies. It is a broad incumbent peer — competing with Longitude for late-stage biotech opportunities but at materially larger AUM and broader mandate.
• Deerfield Management: Deerfield is a large healthcare investment manager spanning venture, private credit, and public equities. It is a broad incumbent peer — overlapping with Longitude in healthcare venture growth but operating at much greater scale across the full healthcare capital stack.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/longitude-capital

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments142 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Longitude Capital